DNLI
Price
$15.43
Change
+$0.64 (+4.33%)
Updated
Sep 5 closing price
Capitalization
2.26B
53 days until earnings call
STOK
Price
$20.68
Change
+$1.05 (+5.35%)
Updated
Sep 5 closing price
Capitalization
1.13B
64 days until earnings call
Interact to see
Advertisement

DNLI vs STOK

Header iconDNLI vs STOK Comparison
Open Charts DNLI vs STOKBanner chart's image
Denali Therapeutics
Price$15.43
Change+$0.64 (+4.33%)
Volume$4.19M
Capitalization2.26B
Stoke Therapeutics
Price$20.68
Change+$1.05 (+5.35%)
Volume$543.6K
Capitalization1.13B
DNLI vs STOK Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. STOK commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and STOK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (DNLI: $15.43 vs. STOK: $20.68)
Brand notoriety: DNLI and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 237% vs. STOK: 64%
Market capitalization -- DNLI: $2.26B vs. STOK: $1.13B
DNLI [@Biotechnology] is valued at $2.26B. STOK’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • STOK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than STOK.

Price Growth

DNLI (@Biotechnology) experienced а +1.05% price change this week, while STOK (@Biotechnology) price change was +4.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.26B) has a higher market cap than STOK($1.13B). STOK YTD gains are higher at: 87.489 vs. DNLI (-24.289). STOK has higher annual earnings (EBITDA): 42.3M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. STOK (248M). STOK has less debt than DNLI: STOK (2.3M) vs DNLI (46.6M). STOK has higher revenues than DNLI: STOK (200M) vs DNLI (0).
DNLISTOKDNLI / STOK
Capitalization2.26B1.13B199%
EBITDA-521.52M42.3M-1,233%
Gain YTD-24.28987.489-28%
P/E RatioN/A23.77-
Revenue0200M-
Total Cash899M248M363%
Total Debt46.6M2.3M2,030%
FUNDAMENTALS RATINGS
DNLI vs STOK: Fundamental Ratings
DNLI
STOK
OUTLOOK RATING
1..100
1992
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9746
PRICE GROWTH RATING
1..100
6035
P/E GROWTH RATING
1..100
999
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (60) in the null industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than DNLI’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to DNLI’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for DNLI (97) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than DNLI’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as DNLI (60) in the Biotechnology industry. This means that STOK’s stock grew similarly to DNLI’s over the last 12 months.

STOK's P/E Growth Rating (9) in the null industry is significantly better than the same rating for DNLI (99) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLISTOK
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 18 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 6 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COSAX12.820.07
+0.55%
Columbia Overseas Core A
PMJAX11.13N/A
N/A
PIMCO RAE US Small A
ARDEX6.19N/A
N/A
AMG River Road Dividend All Cap Value N
BRUMX16.89-0.06
-0.35%
MFS Blended Research Value Equity R4
JDVVX24.98-0.09
-0.36%
JHancock Disciplined Value R5

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+4.33%
NRIX - DNLI
58%
Loosely correlated
+8.66%
BEAM - DNLI
55%
Loosely correlated
+12.62%
OCUL - DNLI
55%
Loosely correlated
+7.09%
RGNX - DNLI
53%
Loosely correlated
+3.08%
IDYA - DNLI
52%
Loosely correlated
+5.15%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+5.35%
IDYA - STOK
50%
Loosely correlated
+5.15%
QTTB - STOK
49%
Loosely correlated
+0.60%
SYRE - STOK
47%
Loosely correlated
+0.06%
IMNM - STOK
47%
Loosely correlated
+7.35%
DNLI - STOK
47%
Loosely correlated
+4.33%
More